Psychiatry Tomorrow Adding SPRAVATO® in Your Practice: A Practical Guide
32 snips
May 5, 2023 
Brittainy Wagner, a revenue cycle management consultant and founder of Tidemark VA Services, shares her expertise on implementing SPRAVATO® in psychiatric practices. They discuss Esketamine's role in treating resistant depression and the complexities of navigating the REMS program. The conversation includes effective billing strategies, insurance reimbursement challenges, and the integration of Osmind EHR to streamline procedures. Learn how to establish a profitable practice while ensuring patient comfort and navigating administrative hurdles.
AI Snips
Chapters
Transcript
Episode notes
SPRAVATO® Approval and Access
- SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression and acute suicidality in adults.
- Its insurance coverage improves access compared to IV or IM ketamine.
How SPRAVATO® Works and Is Administered
- SPRAVATO® is a nasal spray self-administered by patients in-office only, with doses of 56 or 84 mg.
- It works as an NMDA receptor antagonist with rapid antidepressant effects.
REMS Program Safety Requirements
- SPRAVATO® requires administration under a REMS program for safety, including strict two-hour in-office observation.
- This monitoring prevents early patient discharge despite their wishes.